Mylan Finalizes Settlement Agreement With DOJ For $465M
Zacks Investment Research | Aug 18, 2017 04:18AM ET
Mylan N.V. (NASDAQ:MYL) recently announced that its subsidiaries, Mylan Inc. and Mylan Specialty L.P., have signed an agreement with the U.S. Department of Justice (DOJ) and two other relators. The agreement finalizes the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.
The settlement resolves claims which relates to the classification of EpiPen Auto-Injector and EpiPen Jr Auto-Injector for purposes of the Medicaid Drug Rebate Program.
DOJ wanted to ascertain whether EpiPen products were properly classified with the Centers for Medicare and Medicaid Services as a non-innovator drug under the applicable definition in the Medicaid Rebate statute. The drugs were subjected to the formula which is used to calculate rebates to Medicaid for such drugs.
We note that Mylan has been under immense pressure since Aug 2016 when the company came under the spotlight for price increase of EpiPen since its acquisition of the drug in 2007, drawing immense criticism from lawmakers, consumers and the common people alike. Further, Mylan made it to the headlines for wrongly classifying EpiPen as a generic product in the Medicaid Drug Rebate Program. The misclassification implied that Mylan has been vastly underpaying rebates to Medicaid for the drug for a long time than it would have if the drug was classified as a branded one.
EpiPen Auto-Injector was classified as a non-innovator drug with CMS before Mylan acquired the product in 2007 based on longstanding written guidance from the federal government.
Nevertheless, the settlement provides for resolution of all potential Medicaid rebate liability claims by the federal government, as well as potential claims by certain hospitals and other covered entities that participate in the 340B Drug Pricing Program. Moreover, Mylan will reclassify EpiPen Auto-Injector for purposes of the Medicaid Drug Rebate Program and pay the rebate applicable to innovator products, effective Apr 1.
Mylan’s stock has fallen 16.7% year to date compared with the industry’s decline of 14.9%.
Mylan’s second-quarter results were dismal as the company missed on both earnings and sales estimates due to challenges in North America. The cut in annual guidance was also disappointing. Ongoing challenges in the U.S. and uncertain regulatory environment in the region has led the company to defer all major launches in the U.S. from the 2017 guidance to 2018 including generic version of GlaxoSmithKline Inc. (NYSE:GSK) asthma drug Advair Diskusand generic Copaxone.
Get The News You Want
Meanwhile, Mylan's Biologics License Application for proposed biosimilar version of Roche Holdings (OTC:RHHBY) Herceptin is currently under review by FDA. The anticipated FDA goal date set under the Biosimilar User Fee Act is Sep3. We expect investor focus on the same.
Zacks Rank
Mylan currently carries a Zacks Rank #5 (Strong Sell).
A better-ranked stock in the health care sector is Gilead Sciences, Inc. (NASDAQ:GILD) which carriesa Zacks Rank #2 (Buy). You can see .
Gilead’s earnings per share estimates increased from $7.92 to $8.53 for 2017, over the last 30 days following strong results in the second quarter. The company delivered positive earnings surprises in three of the trailing four quarters, with an average beat of 8.18%.
4 Surprising Tech Stocks to Keep an Eye On
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.